A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib

Molecular Partners AG10 sites in 1 country8 target enrollmentMarch 22, 2018

ConditionsEGFR-mutated NSCLC (Disorder)

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: EGFR-mutated NSCLC (Disorder)
Sponsor: Molecular Partners AG
Enrollment: 8
Locations: 10
Primary Endpoint: Estimate the objective response rate (ORR)
Status: Terminated
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with EGFR mutated, advanced, non squamous NSCLC after tumor progression on osimertinib and on or after the most recent therapy.

MP0250 is a multi-DARPin® protein with three specificities, able to simultaneously neutralize the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also to bind to human serum albumin (HSA) to give an increased plasma half-life and potentially enhanced tumor penetration.

Registry

clinicaltrials.gov

Start Date

March 22, 2018

End Date

April 24, 2020

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Molecular Partners AG

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically confirmed metastatic or unresectable locally advanced non-squamous NSCLC with documented EGFR mutation-positive disease
•Radiologically documented disease progression on previous osimertinib treatment.
•Radiologically documented disease progression on or after most recent antitumor therapy.
•Measurable disease according to RECIST 1.
•Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0
•Men and women ≥18 years old on the day of signing informed consent.
•Adequate hematological, hepatic and renal function prior to first dose
•Serum albumin concentration ≥30 g/L
•Potassium and magnesium within normal range

Exclusion Criteria

•Necrotic tumors or tumors close to large blood vessels that may impose an increased bleeding risk when treated with anti-VEGF agents.
•Second malignancy that is currently clinically significant or required active intervention during the period of 12 months prior to Screening, except early stage non-melanoma skin cancer treated with curative intent.
•Known pre-existing interstitial or inflammatory lung disease.
•Clinical signs of or documented leptomeningeal carcinomatosis. Features such as headache, nuchal rigidity, and photophobia may indicate meningeal involvement.
•Known brain metastases who are clinically unstable
•Prohibited anti-NSCLC therapies and not having recovered from related AEs to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1
•Any investigational drug within 28 days prior to study treatment.
•Current participation in any other interventional clinical study (except survival follow up).
•Neuropathy as residual toxicity after prior antitumor therapy Grade \>2
•Patients taking medications that have the potential to prolong the QT interval

Outcomes

Primary Outcomes

Estimate the objective response rate (ORR)

Time Frame: 6 months

Tumor response will be assessed based on RECIST 1.1 by using CT or MRI

Secondary Outcomes

duration of response (DOR)(9 months)
time to response (TTR)(4 months)
pharmacokinetics(15 months)
Incidence and severity of treatment-emergent adverse events (TEAEs) graded according to CTCAE, v4.03.(15 months)
progression free survival (PFS)(12 months)
overall survival (OS)(24 months)
Incidence of anti-drug (MP0250) antibody formation(15 months)